Literature DB >> 16333030

Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.

Joan S Lewis1, Kathleen Meeke, Clodia Osipo, Eric A Ross, Noman Kidawi, Tianyu Li, Eric Bell, Navdeep S Chandel, V Craig Jordan.   

Abstract

BACKGROUND: We previously developed an estrogen receptor (ER)-positive breast cancer cell line (MCF-7:5C) that is resistant to long-term estrogen deprivation and undergoes rapid and complete apoptosis in the presence of physiologic concentrations of 17beta-estradiol. Here, we investigated the role of the mitochondrial apoptotic pathway in this process.
METHODS: Apoptosis in MCF-7:5C cells treated with estradiol, fulvestrant, or vehicle (control) was investigated by annexin V-propidium iodide double staining and 4',6-diamidino-2-phenylindole (DAPI) staining. Apoptosis was also analyzed in MCF-7:5C cells transiently transfected with small interfering RNAs (siRNAs) to apoptotic pathway components. Expression of apoptotic pathway intermediates was measured by western blot analysis. Mitochondrial transmembrane potential (psim) was determined by rhodamine-123 retention assay. Mitochondrial pathway activity was determined by cytochrome c release and cleavage of poly(ADP-ribose) polymerase (PARP) protein. Tumorigenesis was studied in ovariectomized athymic mice that were injected with MCF-7:5C cells. Differences between the treatment groups and control group were determined by two-sample t test or one-factor analysis of variance. All statistical tests were two-sided.
RESULTS: MCF-7:5C cells treated with estradiol underwent apoptosis and showed increased expression of proapoptotic proteins, decreased psim, enhanced cytochrome c release, and PARP cleavage compared with cells treated with fulvestrant or vehicle. Blockade of Bax, Bim, and p53 mRNA expression by siRNA reduced estradiol-induced apoptosis relative to control by 76% [95% confidence interval (CI) = 73% to 79%, P < .001], 85% [95% CI = 90% to 80%, P < .001], and 40% [95% CI = 45% to 35%, P < .001], respectively, whereas blockade of FasL by siRNA had no effect. Estradiol caused complete regression of MCF-7:5C tumors in vivo.
CONCLUSION: The mitochondrial pathway of apoptosis plays a critical role in estradiol-induced apoptosis in long-term estrogen-deprived breast cancer cells. Physiologic concentrations of estradiol could potentially be used to induce apoptosis and tumor regression in tumors that have developed resistance to aromatase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16333030     DOI: 10.1093/jnci/dji400

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  109 in total

1.  Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.

Authors:  Garnet L Anderson; Rowan T Chlebowski; Aaron K Aragaki; Lewis H Kuller; JoAnn E Manson; Margery Gass; Elizabeth Bluhm; Stephanie Connelly; F Allan Hubbell; Dorothy Lane; Lisa Martin; Judith Ockene; Thomas Rohan; Robert Schenken; Jean Wactawski-Wende
Journal:  Lancet Oncol       Date:  2012-03-07       Impact factor: 41.316

Review 2.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

3.  Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Authors:  V Craig Jordan; Ramona Curpan; Philipp Y Maximov
Journal:  J Natl Cancer Inst       Date:  2015-04-02       Impact factor: 13.506

4.  Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study.

Authors:  Chrisandra Shufelt; C Noel Bairey Merz; Mary B Pettinger; Lydia Choi; Rowan Chlebowski; Carolyn J Crandall; Simin Liu; Dorothy Lane; Ross Prentice; JoAnn E Manson
Journal:  Menopause       Date:  2018-09       Impact factor: 2.953

5.  Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors.

Authors:  Zeynep Madak-Erdogan; Karen J Kieser; Sung Hoon Kim; Barry Komm; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Mol Endocrinol       Date:  2008-07-10

6.  Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer.

Authors:  Joan S Lewis-Wambi; Ramona Swaby; Helen Kim; V Craig Jordan
Journal:  J Steroid Biochem Mol Biol       Date:  2009-01-09       Impact factor: 4.292

7.  The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.

Authors:  V Craig Jordan; Ifeyinwa Obiorah; Ping Fan; Helen R Kim; Eric Ariazi; Heather Cunliffe; Hiltrud Brauch
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

8.  Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time.

Authors:  Eric A Ariazi; Heather E Cunliffe; Joan S Lewis-Wambi; Michael J Slifker; Amanda L Willis; Pilar Ramos; Coya Tapia; Helen R Kim; Smitha Yerrum; Catherine G N Sharma; Emmanuelle Nicolas; Yoganand Balagurunathan; Eric A Ross; V Craig Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-19       Impact factor: 11.205

9.  Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol.

Authors:  I E Obiorah; V C Jordan
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

10.  Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.

Authors:  Ping Fan; V Craig Jordan
Journal:  Steroids       Date:  2014-06-12       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.